“Indian Contract Manufacturing - A Hot Opportunity” is the recent report by RNCOS that gives first hand information on the thriving contract manufacturing market in India and the opportunities it is opening up for global players.
The Indian contract manufacturing market was worth US$ 874 Million in 2007. Although this market presently occupies a fraction of the total global opportunity, the future potential of the market seems immense. The Indian contract manufacturing market, with its low cost advantage, strong chemistry and reverse engineering capabilities, improving infrastructure and strong incentives from the government, is expected to grow strongly in the next five years. By 2012, the Indian industry is expected to grab nearly 8% of the total global market.
The report comprehensively evaluates the contract manufacturing market in India, analyzing its present market size, key segments, capabilities, and the future direction of growth. It also gives a statistical and analytical insight into the various factors vital for drug manufacturing, such as the competitive advantage/disadvantage of India vis-à-vis developed countries on various parameters such as cost, intellectual property and infrastructure etc.
Key Findings
- Indian contract manufacturing market is expected to grow in excess of CAGR 37% between 2007 and 2012.
- Most companies presently outsource APIs and intermediates from India. Moreover, India is also becoming a major hub for outsourcing formulations.
- Many Indian manufacturers have upgraded their manufacturing plants, which has enabled India to have a number of plants certified by the FDA, EDQM and various other regulatory agencies.
- The cost of secondary manufacturing in India is around 13%-15% of the cost in the US, the UK and Germany, with companies making substantial savings on costs of plant set up, labor and operations.
- India has more than four times the total drug manufacturing staff than the US and more than 12 times that in the UK.
- Growth of the contract manufacturing market is expected to provide a major boost to the pharma machinery market in India, which is expected to register revenues up to US$ 822 Million by 2010.
- Strong appreciation of the Indian Rupee against the US Dollar is having a detrimental effect on the profits of many Indian contract manufacturers.
Key Issues & Facts Analyzed
- Evaluation of the total size and growth rate of the contract manufacturing market.
- Analysis of key segments.
- Evaluation of India’s capability in pharmaceutical manufacturing.
- Analysis of the total costs incurred while manufacturing a drug in India (such as cost of land, construction, labor, utilities, freight etc).
- Analysis of the country’s pharma-related human resources.
- Study of the country’s pharma-related infrastructure.
- Analysis of the key opportunities created by the industry.
- Analysis of key players, including their business overview, key facts, and financial information.
Research Methodology Used
Information Sources
Information has been sourced from books, newspapers, trade journals, and white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to more than 3000 paid databases.
Analysis Methods
The analysis methods include ratio analysis, historical trend analysis, linear regression analysis using software tools, judgmental forecasting and cause and effect analysis.
